AMC Sciences delivers autonomous proteomic analysis services, employing an 'omics'-based methodology to validate alterations in the expression levels of specific proteins induced by internal disease factors, external stress factors, and the evolution of treatment and disease. Leveraging this approach, AMC Sciences provides next-generation analysis services aimed at uncovering various disease-related biomarkers in the field of clinical research.
Label-free Quantification, Isobaric Labelling Quantification (TMT or iTRAQ reagent)
Selected Reaction Monitoring
Phosphorylation, Glycosylation, Ubiquitination, etc.
Antibody drug, Antibody-drug conjugation, Glycosylation analysis
AMC Sciences offers various drugability evaluation services to understand the drug metabolism and pharmacokinetic (DMPK) characteristics ofnew chemical entities (NCE)/new molecular entities(NME) during the early stages of drug discovery. By facilitating the optimal optimization of lead compounds, AMC Sciences increases the likelihood of success in the drug development process for its clients.
Sample preparation and development of quantitative analysis method using LC-MS/MS
Analysis of drug concentrations in blood or tissue
Analysis of metabolites
Parallel artificial membrane permeability assay (PAMPA)
Caco-2 permeability assay
Protein binding assay
Microsomal stability
Plasma stability
CYP inhibition study
In vitro metabolite identification (Met ID)
Rodent (mouse/rat) full PK study
Tissue distribution experiments (ex. Brain, tumor)
N-in-one PK study
Leveraging the extensive collection of patient tissues at Asan Medical Center, AMC Sciences generates and examines tissue microarrays of normal and cancer tissues. This tissue analysis service plays a pivotal role in investigating and validating new drug indications and predicting potential side effects.
Contact : bd@amcsciences.com
Go Link